Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CPT2 | P23786 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 3/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16005836 | 1.00 | HMGCR (0.79) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| Meglutol SCHEMBL8718194 | 0.89 | HMGCR (1.00) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| Meglutol SCHEMBL28443 | 0.89 | HMGCR (1.00) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL7041938 | 0.89 | HMGCR (0.58) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| Meglutol SCHEMBL31372614 | 0.79 | HMGCR (0.79) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL14665978 | 0.77 | HMGCR (0.46) | HMGCRCHRM1TBXA2RADRA1AALDH1A1 | |
| SCHEMBL17227383 | 0.77 | HMGCR (0.75) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL15693959 | 0.77 | HMGCR (0.75) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL16882363 | 0.77 | HMGCR (0.75) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL126376 | 0.77 | HMGCR (0.75) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202758-A1 | CORE 2GLCNAC-T INHIBITORS | MS THERAPEUTICS LIMITED (GB) | 2012-08-09 | — | — | US | disclosed |
| US-8197794-B2 | Core 2 GlcNAc-T inhibitors | MS THERAPEUTICS LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20120142620-A1 | CORE 2 GLCNAC-T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142620-A1 | CORE 2 GLCNAC-T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-7998943-B2 | Treating a subject in need of therapy for a condition involving detrimental activity of the enzyme Core 2 GlcNAc-T(Core 2-N-acetylglucosaminyl transferase) comprising administration of a steroid compound inhibitor thereof; multiple sclerosis; antiinflammatory, anticarcinogenic agents | BTG INTERNATIONAL LIMITED (GB) | 2011-08-16 | — | — | US | disclosed |
| US-7998943-B2 | Treating a subject in need of therapy for a condition involving detrimental activity of the enzyme Core 2 GlcNAc-T(Core 2-N-acetylglucosaminyl transferase) comprising administration of a steroid compound inhibitor thereof; multiple sclerosis; antiinflammatory, anticarcinogenic agents | BTG INTERNATIONAL LIMITED (GB) | 2011-08-16 | — | — | US | disclosed |
| US-20100256077-A1 | Core 2GlcNAc-T inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| US-20100048495-A1 | Core 2 GlcNAc-T inhibitors III | BTG INTERNATIONAL LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048495-A1 | Core 2 GlcNAc-T inhibitors III | BTG INTERNATIONAL LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048496-A1 | Core 2 GlcNAc-T inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048496-A1 | Core 2 GlcNAc-T inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20080182801-A1 | Core 2 glcnac-t inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20070010461-A1 | Core 2 GlcNAc-T inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
| US-20070010461-A1 | Core 2 GlcNAc-T inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
| US-20070010462-A1 | Core 2 GlcNAc-T inhibitors III | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
| US-20070010462-A1 | Core 2 GlcNAc-T inhibitors III | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202758-A1 | CORE 2GLCNAC-T INHIBITORS | CSGALNACT1, SACM1L, ENGASE | HMGCR 1548/4885CHRM1 949/4885TBXA2R 4205/4885 |
| US-20100256077-A1 | Core 2GlcNAc-T inhibitors | CSGALNACT1, SACM1L, ENGASE | HMGCR 1503/4885CHRM1 916/4885TBXA2R 4188/4885 |
| US-20120142620-A1 | CORE 2 GLCNAC-T INHIBITORS | MAN2A1, CSGALNACT1, MAN2B1 | HMGCR 1223/4885CHRM1 1980/4885TBXA2R 2278/4885 |
| US-20100048496-A1 | Core 2 GlcNAc-T inhibitors | MAN2A1, CSGALNACT1, MAN2B1 | HMGCR 1223/4885CHRM1 1980/4885TBXA2R 2278/4885 |
| US-20070010461-A1 | Core 2 GlcNAc-T inhibitors | MAN2A1, CSGALNACT1, MAN2B1 | HMGCR 1223/4885CHRM1 1980/4885TBXA2R 2278/4885 |
| US-20100048495-A1 | Core 2 GlcNAc-T inhibitors III | CSGALNACT1, ENGASE, GALNT6 | HMGCR 1523/4885CHRM1 1903/4885TBXA2R 3790/4885 |
| US-20070010462-A1 | Core 2 GlcNAc-T inhibitors III | CSGALNACT1, ENGASE, GALNT6 | HMGCR 1483/4885CHRM1 1883/4885TBXA2R 3778/4885 |
| US-20080182801-A1 | Core 2 glcnac-t inhibitors | CSGALNACT1, ENGASE, GALNT6 | HMGCR 1671/4885CHRM1 1656/4885TBXA2R 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.